Quick Answer
Spero Therapeutics, Inc. reported Stockholders Equity of $59.02 million for the year ending 2025.
- Spero Therapeutics, Inc. showed an increase of +28.0% in Stockholders Equity from 2024 to 2025.
- This data is from Spero Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: -$82.19 million | Q1 2018: $74.54 million | Q2 2018: $65.31 million | Q3 2018: $125.20 million | Q1 2019: $112.97 million | Q2 2019: $109.31 million | Q3 2019: $92.68 million | Q1 2020: $82.43 million | Q2 2020: $73.71 million | Q3 2020: $132.79 million | Q1 2021: $118.85 million | Q2 2021: $90.25 million | Q3 2021: $111.90 million | Q1 2022: $62.47 million | Q2 2022: $35.92 million | Q3 2022: $32.48 million | Q1 2023: $64.84 million | Q2 2023: $54.78 million | Q3 2023: $53.71 million | Q1 2024: $96.25 million | Q2 2024: $80.50 million | Q3 2024: $65.51 million | Q1 2025: $33.81 million | Q2 2025: $32.83 million | Q3 2025: $26.49 million.
- Over the full 10 years of available data (2016 to 2025), Spero Therapeutics, Inc.'s Stockholders Equity has grown by 229.9%.
- Historical annual values: Fiscal year 2025: $59.02 million | Fiscal year 2024: $46.12 million | Fiscal year 2023: $106.89 million | Fiscal year 2022: $75.93 million | Fiscal year 2021: $88.29 million | Fiscal year 2020: $132.04 million | Fiscal year 2019: $74.57 million | Fiscal year 2018: $115.50 million | Fiscal year 2017: $84.60 million | Fiscal year 2016: -$45.44 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: